Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | PTAFR | P25105 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251817 | 0.92 | EPHX2 (0.67) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4251826 | 0.91 | EPHX2 (0.66) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL13701848 | 0.90 | EPHX2 (0.67) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4253967 | 0.89 | EPHX2 (0.64) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4255885 | 0.89 | EPHX2 (0.64) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4250480 | 0.89 | EPHX2 (0.66) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4248361 | 0.89 | EPHX2 (0.63) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4249940 | 0.88 | EPHX2 (0.64) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4253819 | 0.88 | EPHX2 (0.64) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 | |
| SCHEMBL4250838 | 0.87 | EPHX2 (0.69) | EPHX2ALOX5TBXAS1SLC6A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | EPHX2 2/4885ALOX5 60/4885TBXAS1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.